Biomarin Pharmaceutical Inc.

Novartis Ag

Xoma Technology Ltd.

Kidisti Araya

Augustus O Okhamafe

Michel Claude Vellard

Vish Koppaka

Bao-lu Chen

Xiaofeng Lu

This invention provides compositions of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase (GALNS), and pharmaceutical compositions and formulations thereof, methods of producing and purifying GALNS, and its use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the GALNS enzyme, e.g., Mucopolysaccharidosis IVa (MPS IVa or Morquio A syndrome).

Manufacture of active highly phosphorylated human N-acetylgalactosamine-6-sulfatase and uses thereof

Stable liquid pharmaceutical compositions comprising an antagonist anti-CD40 antibody as a therapeutically or prophylactically active component and methods useful in their preparation are provided. These compositions comprise the antagonist anti-CD40 antibody, a buffering agent to maintain the pH of the composition between about pH 5.0 and about pH 7.0, and an amount of arginine-HCl sufficient to render the liquid composition near isotonic. The stable liquid antagonist anti-CD40 antibody-containing pharmaceutical compositions of the invention find use in methods for treating proliferative diseases and diseases having an autoimmune and/or inflammatory component.

Antagonist anti-CD40 antibody pharmaceutical compositions

Growing community of inventors

Berkeley, CA, United States of America

Kidisti Araya